AAG
CRSP icon

Armstrong Advisory Group’s CRISPR Therapeutics CRSP Stock Holding History

Armstrong Advisory Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-31
Closed -$1.48K – 988
2026
Q1 		$1.48K Hold
31
– – ﹤0.01% 895
2025
Q4 		$1.63K Hold
31
– – ﹤0.01% 884
2025
Q3 		$2.01K Buy
+31
New +$1.78K ﹤0.01% 859

Other funds holding CRSP

CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
WETS
Wealth Enhancement Trust Services Sioux Falls, South Dakota $792M AUM
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
BIP
Bouvel Investment Partners Phoenixville, Pennsylvania $442M AUM 70.77% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
IIM
Ipswich Investment Management Beverly, Massachusetts $474M AUM 35.58% 1-Year Est. Return
PFGIA
Patriot Financial Group Insurance Agency Westborough, Massachusetts $974M AUM 29.77% 1-Year Est. Return
BAM
Brave Asset Management Summit, New Jersey $467M AUM 33.05% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

Armstrong Advisory Group's CRSP Position: Q2 2026 in Review

Armstrong Advisory Group sold out of CRISPR Therapeutics (CRSP) in Q2 2026, closing a stake of 31 shares — an estimated $1.48K sold.

Armstrong Advisory Group first reported a position in CRSP in Q3 2025 and held it in 3 quarters. The position peaked at $2.01K in Q3 2025. 59 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Armstrong Advisory Group reported no remaining CRISPR Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Armstrong Advisory Group sold 31 CRISPR Therapeutics shares in Q2 2026, an estimated $1.48K.
  • Armstrong Advisory Group first reported a position in CRISPR Therapeutics in Q3 2025 and held it in 3 quarters.
  • Armstrong Advisory Group's CRISPR Therapeutics position peaked at $2.01K in Q3 2025.
  • 59 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Armstrong Advisory Group's 13F filing for Q2 2026, filed 13 Jul 2026.